Compare Gilead Sciences, Inc. (GILD) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Match Group Inc — how do they compare? Gilead Sciences, Inc. trades at $147.1 (market cap $182.09B), while Match Group Inc trades at $41.48 (market cap $9.37B). The key difference: Gilead Sciences, Inc. is far larger — about 19.4× Match Group Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Match Group Inc for 115 Days on average.
| GILD | MTCH | |
|---|---|---|
Market Cap | $182.09B | $9.37B |
Volume | 4,960,247 | 2,544,041 |
Sector | Health | Media |
52-Week High | $155.80 | $44.40 |
52-Week Low | $116.74 | $28.90 |
Typical Hold Time | 111 Days | 115 Days |
Enterprise Value | $205.15B | $12.34B |
Dividend Yield | 2.23% | 1.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Match Group (MTCH) trades at $41.50, up 2.17% with a bullish technical outlook. The stock shows strong fundamentals with 74.8% gross margins and consistent earnings beats in recent quarters. Revenue remains stable at $3.5B while net income margin improved to 20.17% in 2025. Analyst consensus is bullish with a $42.29 price target, and institutional activity shows continued interest despite recent selling by some advisors.
MTCH presents a compelling investment case with reasonable valuation (P/E 14.48) and strong cash flow generation. Key risks include high debt levels ($3.85B) and competitive pressures in the dating app market. The company's product innovation and Hinge's growth provide upside potential, though execution risks and market saturation concerns warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
